BeyondSpring (NASDAQ:BYSI) Issues Quarterly Earnings Results
BeyondSpring (NASDAQ:BYSI) reported a quarterly loss of $0.05 per share. The stock fell 2.5% to $2.15, with a trading volume of 18,532 shares. Geode Capital Management increased its stake in the company by 951.4% in Q2. Weiss Ratings reiterated a 'sell' rating for BeyondSpring. The company focuses on cancer therapies, with its lead asset Plinabulin in Phase III trials for non-small cell lung cancer. Analysts suggest other stocks as better investments.
BeyondSpring (NASDAQ:BYSI - Get Free Report) released its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, Zacks reports.
BeyondSpring Stock Down 2.5%
BeyondSpring stock traded down $0.06 during midday trading on Wednesday, reaching $2.15. The stock had a trading volume of 18,532 shares, compared to its average volume of 36,532. BeyondSpring has a 52-week low of $0.98 and a 52-week high of $3.44. The firm has a market cap of $86.51 million, a price-to-earnings ratio of -21.55 and a beta of 0.26. The company has a fifty day moving average of $1.85 and a 200 day moving average of $1.98.
Institutional Trading of BeyondSpring
A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC boosted its position in shares of BeyondSpring Inc. (NASDAQ:BYSI - Free Report) by 951.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 256,212 shares of the company's stock after purchasing an additional 231,844 shares during the quarter. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 40.29% of the company's stock.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of BeyondSpring in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of "Sell".
Check Out Our Latest Stock Analysis on BeyondSpring
BeyondSpring Company Profile
(Get Free Report)BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
Further Reading
- Five stocks we like better than BeyondSpring
- ETF Screener: Uses and Step-by-Step Guide
- Why Bulls Should Want a Bigger Drop in Palantir Stock
- Consumer Discretionary Stocks Explained
- Papa John's $2.7 Billion Takeover Bid: A Price on Untapped Value
- Profitably Trade Stocks at 52-Week Highs
- Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in BeyondSpring Right Now?
Before you consider BeyondSpring, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeyondSpring wasn't on the list.
While BeyondSpring currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
